ARCHIVES

Phase II Study Cohort Fails To Overcome Erlotinib Resistance

This article is from The Cancer Letter archive.

Vol. 36 No. 4 | April 26, 2013

Download PDF Visit The Full Archive

Related Articles

Nucynta ER Approved For Managing Chronic Pain In Adults

September 30, 2011

Early ADT Doesn’t Offer Survival Advantage—ASCO

April 27, 2007

DCE Board Approves Concept For New $850,000 Year Grant Program To Study Viruses In Cervical Cancer

November 9, 1984

Price Increase

July 22, 1983

FDA Approves Generic Oncology Injectable Currently In Shortage

September 27, 2013

Patient Groups Are Focus of New Alliances In a Shift of Cancer Advocacy Agenda

May 31, 1996